Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Vanda’s Nereus: Motion Sickness Drug Lacked Adequate Nonclinical Cumulative Exposure Data
Feb 20 2026
•
By
Sue Sutter
The FDA approved Nereus for motion-induced vomiting.
(Citeline/Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Drug Review Profiles
More from United States